our data indicate that while central pathology review is mandatory for quality assurance in malignant lymphoma ( ml ) and hodgkin 's disease ( hd ) protocols , a two-tier review mechanism is not necessary for adequate quality control .
C0024299
malignant lymphoma
C0019829
hodgkin 's